Loperamide

Loperamide
Health risk	At therapeutic doses: Low At high abuse doses: High (cardiotoxicity, death)
Addiction risk	At therapeutic doses: Low With chronic high‑dose use: Moderate (physical & psychological dependence)
Legal risk	Over-the-counter (OTC) in most jurisdictions; behind‑the‑counter or restricted sale in some regions

Loperamide (sold under various trade names including Diamode, Imodium, Maalox Anti‑Diarrheal and Pepto Diarrhea Control) is a medication primarily used to treat diarrhea. It works by slowing the movement of the gut, which helps decrease the frequency of bowel movements. Loperamide is classified as an opioid receptor agonist and acts on the mu‑opioid receptors in the intestine. However, unlike other opioids, it does not significantly affect the central nervous system at typical doses, meaning it does not provide pain relief or produce a high.

The drug is available over‑the‑counter (OTC) in most countries.

Background

Loperamide was first synthesised in 1969 and approved for medical use in 1976. It was designed to be an anti‑diarrhoeal opioid that, unlike diphenoxylate or other opioids, does not cross the blood‑brain barrier, minimising the potential for abuse and dependence. Today loperamide is included in the World Health Organization’s List of Essential Medicines and is one of the most widely used anti‑diarrhoeal agents globally. Despite a relatively good safety profile at therapeutic doses, reports of abuse at very high doses began emerging in the early 2000s, driven by attempts to self‑manage opioid withdrawal or to achieve euphoria. These practices have drawn serious attention because of life‑threatening cardiac complications.

Medical uses

• Short‑term treatment of acute diarrhoea (with or without an infectious cause, alongside treatment of the underlying condition)
• Management of chronic diarrhoea in conditions such as diarrhoea‑predominant irritable bowel syndrome (IBS‑D)
• Reduction of stool frequency and volume in patients with ileostomies or colostomies
• Symptom control in travellers’ diarrhoea

Loperamide only controls the symptom of diarrhoea. It should not be used without medical advice if bloody diarrhoea, high fever, or suspected infection with invasive pathogens such as Clostridium difficile is present.

Mechanism of action

Loperamide is a selective agonist of mu‑opioid receptors in the myenteric plexus. Activation of these receptors reduces the release of acetylcholine and prostaglandins, thereby slowing peristalsis and increasing intestinal transit time. This allows greater absorption of water and electrolytes, firming the stool. Loperamide also increases anal sphincter tone and reduces the sensation of urgency.

The lack of central nervous system effects at normal doses is due to the efflux transporter P‑glycoprotein (P‑gp) at the blood‑brain barrier, which actively pumps the drug out of the brain. At very high doses this system becomes saturated, allowing small amounts of loperamide to enter the brain, which can lead to euphoria or respiratory depression.

Appeal

Although loperamide does not produce euphoria at standard doses, it is sometimes abused by people who use drugs for the following reasons:

• Self‑management of opioid withdrawal: Many individuals take high doses (often 20–50 times the therapeutic dose) to relieve withdrawal symptoms such as muscle aches, diarrhoea, sweating and restlessness. The opioid effect in the gut and the small amount that reaches the brain can partially ease withdrawal.
• Easy access and low cost: It is an over‑the‑counter medicine, inexpensive and available in most pharmacies.
• Not detected on routine drug screens: Loperamide is not identified by standard urine opiate screening tests and is perceived as a “legal” substance that attracts less scrutiny.
• Internet forums: Personal accounts posted online describing the use of loperamide for withdrawal or to get high (slang terms include “lope” or “poor man’s methadone”) have encouraged some people to try dangerously high doses.

Dosing

Therapeutic use (acute diarrhoea)

Adults: initially 4 mg (two 2 mg capsules/tablets), then 2 mg after each loose bowel movement. Maximum recommended over‑the‑counter daily dose: 8 mg (in some countries 12–16 mg on prescription). Do not exceed the maximum dose.

Children: dosed by weight and age, usually only on medical advice.

Doses associated with abuse (dangerous – provided for awareness and warning only)

Users aiming to manage withdrawal or to achieve euphoria have reported taking from 20 mg to over 200 mg per day, sometimes as a single dose. Such amounts are strongly associated with cardiac toxicity and death. Never exceed the therapeutic dose.

Risks

1. Cardiac toxicity (primary risk at high doses)

At high doses, loperamide inhibits cardiac hERG potassium channels, leading to QT‑interval prolongation, dangerous arrhythmias such as Torsades de Pointes, and cardiac arrest. Numerous cases of sudden cardiac death have been recorded. This risk is amplified by concurrent use of CYP3A4/CYP2C8 inhibitors or P‑gp inhibitors, which increase the amount of drug entering the brain.

2. Respiratory depression

At supra‑therapeutic doses that partially overcome the blood‑brain barrier, respiratory depression similar to that produced by other opioids can occur, especially when combined with other CNS depressants such as alcohol or benzodiazepines.

3. Severe gastrointestinal effects

Severe, intractable constipation, bowel obstruction, abdominal distension and, rarely, toxic megacolon.

4. Neuromuscular symptoms

Drowsiness, dizziness, impaired consciousness and, at high doses, miosis (pupil constriction).

5. Dependence and tolerance

Long‑term high‑dose use can lead to tolerance and physical dependence. Abrupt discontinuation may precipitate an opioid‑like withdrawal syndrome.

Interactions

Combining loperamide with the substances listed below can dramatically increase the risk of adverse effects and should be avoided:

• CYP3A4 and CYP2C8 inhibitors: e.g. ketoconazole, itraconazole, ritonavir, clarithromycin, and grapefruit juice. These reduce the metabolism of loperamide and raise its plasma concentration.
• P‑glycoprotein inhibitors: e.g. quinidine, verapamil, ciclosporin and some antifungals. By blocking the efflux of loperamide from the brain, they increase the likelihood of central effects and respiratory depression.
• Other QT‑prolonging drugs: e.g. methadone, citalopram, Class I and III antiarrhythmics, certain antipsychotics and antibiotics (levofloxacin, azithromycin). Concomitant use with high‑dose loperamide multiplies the risk of ventricular arrhythmias.
• CNS depressants: alcohol, benzodiazepines, gabapentinoids and other opioids intensify the risk of profound sedation and respiratory depression.

Addiction

Although loperamide has a low addiction potential at therapeutic doses, repeated high‑dose use for self‑treatment or euphoria can lead to loperamide use disorder. Signs include:

• Compulsive use beyond intended amounts
• Tolerance (need for higher doses to achieve the same effect)
• Inability to cut down or stop use
• Continued use despite awareness of physical and psychological harms
• Withdrawal syndrome on abrupt cessation (muscle aches, rebound diarrhoea, sweating, insomnia, yawning, rhinorrhoea)

Psychological dependence often centres on the fear of returning withdrawal symptoms or diarrhoea. Medically supervised withdrawal, sometimes using a gradual taper or adjunctive medications, is recommended.

Risk mitigation

Given the serious dangers of high‑dose loperamide, harm‑reduction advice includes:

• Never exceed the maximum therapeutic dose. If diarrhoea persists beyond 2 days, consult a healthcare provider.
• When using loperamide to self‑manage opioid withdrawal, be aware that the risk of sudden cardiac death is real and that it is not a safe substitute for standard treatments (e.g. buprenorphine or methadone under medical supervision).
• Strictly avoid concomitant use of QT‑prolonging drugs or CYP3A4/P‑gp inhibitors.
• If high doses are taken (emphasis: this is extremely dangerous), do not use alone, and seek emergency help immediately if palpitations, syncope or fainting occur. We do not endorse the use of high‑dose loperamide.
• Prioritise professional medical care for safe withdrawal and access to evidence‑based substitution therapies. Loperamide should not be considered a long‑term strategy for managing opioid dependence.

Known incidents

• United States (2016–2020): The FDA reported a sharp rise in serious cardiac events and deaths linked to high‑dose loperamide. Between 2010 and 2015, 48 cases of serious cardiac complications, including 10 deaths, were recorded, and the trend continued. In response, the FDA requested manufacturers to consider unit‑dose packaging and limits on the number of units sold.
• Medical case reports: Dozens of cases of Torsades de Pointes and cardiac arrest have been published in journals such as Annals of Emergency Medicine and Clinical Toxicology, involving patients taking 100–800 mg of loperamide daily. Some patients progressed to brain death despite initial resuscitation.
• Online sales: Websites and drug‑use forums have promoted loperamide as “poor man’s methadone”, contributing to a surge in poisonings in remote communities and prisons.
• Canada and the United Kingdom: Sporadic reports of loperamide‑related deaths have prompted review of OTC availability in some regions and the addition of warnings on packaging.